ArticleBiology direct2026
The PTHR1/PKA/CREB1 axis promotes osteosarcoma progression by activating the PVT1/miR-590-3p/AXIN2 ceRNA network to induce epithelial-mesenchymal transition.
Article in Biology direct, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundOsteosarcoma (OS) remains a clinically challenging primary bone tumor because of its strong metastatic potential and unsatisfactory outcomes in advanced cases. Parathyroid hormone receptor 1 (PTHR1), a receptor closely associated with bone-related signaling, has not been fully characterized in OS. This study explored whether PTHR1 contributes to OS progression and clarified the downstream regulatory mechanism involved.
methodsPublic GEO datasets, clinical OS specimens, and cultured OS cells were used to assess PTHR1 expression. Stable PTHR1 knockdown and overexpression OS cell models were established using lentiviral vectors. Cell growth, apoptosis, motility, invasiveness, EMT, and tumor growth were evaluated by CCK-8, flow cytometry, Transwell, Western blot, and xenograft assays. The underlying mechanism was explored using dual-luciferase reporter assays, ChIP-qPCR, pathway intervention, and rescue experiments.
resultsPTHR1 was significantly upregulated in OS tissues and cells. PTHR1 overexpression promoted OS cell proliferation, migration, invasion, EMT, and xenograft tumor growth while suppressing apoptosis, whereas PTHR1 knockdown exerted the opposite effects. Mechanistically, PTHR1 activated the cAMP/PKA/CREB1 pathway, leading to transcriptional upregulation of lncRNA PVT1. PVT1 functioned as a competing endogenous RNA by sponging miR-590-3p, thereby relieving miR-590-3p-mediated repression of AXIN2. AXIN2 further promoted EMT and malignant progression, and AXIN2 overexpression partially reversed the inhibitory effects of PTHR1 knockdown.
conclusionPTHR1 promotes OS progression by activating the CREB1/PVT1/miR-590-3p/AXIN2 regulatory axis and enhancing EMT. This five-component signaling cascade may provide potential biomarkers and therapeutic targets for OS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.